Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue 12, 2006, Pages 1339-1343

  Ahn, J H ^a   Kim, T Y ^a   Kim, Y J ^b   Han, M W ^a   Yoon, T H ^a   Chung, J W ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

Author keywords

Diabetes mellitus; Lipo prostaglandin E1; Sudden hearing loss

Indexed keywords

LIPOPROSTAGLANDIN E1; METHYLPREDNISOLONE; PLACEBO; STEROID; GLUCOCORTICOID; NEUROPROTECTIVE AGENT; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMBOLISM; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTION DEAFNESS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS; DIABETIC NEUROPATHY; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY;

ALPROSTADIL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEARING LOSS, SENSORINEURAL; HUMANS; KOREA; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES;

EID: 33751212437     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01993.x     Document Type: Article

References (24)

1. Whitaker S. Idiopathic sudden hearing loss. Am J Otol 1980; 1: 180-183.
2. Rosen S, Olin P, Rosen HV. Dietary prevention of hearing loss. Acta Otolaryngol 1970; 70: 242-247.
3. Wilson WR, Laird N, Moo-Young G, Soeldner JS, Kavesh DA, MacMeel JW. The relationship of idiopathic sudden hearing loss to diabetes mellitus. Laryngoscope 1982; 92: 155-160.
4. Rust KR, Prazma J, Triana RJ, Michaelis OE, Pillsbury HC. Inner ear damage secondary to diabetes mellitus. II. Changes in aging SHR/N-cp rats. Arch Otolaryngol Head Neck Surg 1992; 118: 397-400.
5. Pelkonen R. Why should we treat hyperglycaemia? Ann Med 1990; 22: 207-209.
6. Kanzaki J, Taiji H, Ogawa K. Evaluation of hearing recovery and efficacy of steroid treatment in sudden deafness. Acta Otolaryngol Suppl 1988; 456: 31-36.
7. Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. Eur Arch Otorhinolaryngol 2001; 258: 477-480.
8. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Ohnishi M et al. Idiopathic sudden hearing loss in patients with type 2 diabetes. Diabetes Res Clin Pract 2004; 63: 205-211.
9. Weng SF, Chen YS, Liu TC, Hsu CJ, Tseng FY. Prognostic factors of sudden sensorineural hearing loss in diabetic patients. Diabetes Care 2004; 27: 2560-2561.
10. Karetova D, Bultas J, Vondracek V, Aschermann M. Alprostadil: modes of actions in peripheral arterial occlusive disease. Am J Ther 1997; 4: 359-363.
11. Ahn JH, Kim MR, Kim HC. Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. Am J Otolaryngol 2005; 26: 245-248.
12. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-20.
13. Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am 1975; 8: 467-473.
14. Spencer JT Jr. Hyperlipoproteinemias in the etiology of inner ear disease. Laryngoscope 1973; 83: 639-678.
15. Ohinata Y, Makimoto K, Kawakami M, Haginomori S, Araki M, Takahashi H. Blood viscosity and plasma viscosity in patients with sudden deafness. Acta Otolaryngol 1994; 114: 601-607.
16. Byl FM. Seventy-six cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope 1977; 87: 817-825.
17. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
18. Giardino I, Brownlee M. The biochemical basis of microvascular diseases. Diabetes Care 1992; 15: 815-819.
19. Salganicoff L, Russo MA. A hypothesis on the consolidation and PGE1-induced deconsolidation of a platelet plug. Platelets 2003; 14: 463-471.
20. Ferreira SH, Vane JR. Prostaglandins: their disappearance from and release into the circulation. Nature 1967; 216: 868-873.
21. Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drugs Exp Clin Res 1986; 12: 681-685.
22. Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 1983; 35: 666-667.
23. Komatsu A, Ohashi K, Oba H, Kakehashi T, Mizushima Y, Shirasawa E et al. Application of lipid microsphere drug delivery system to steroidal ophthalmic preparation. Jpn J Ophthalmol 1988; 32: 41-43.
24. Asakura M, Kato I, Takahashi K, Okada T, Minami S, Takeyama I et al. Increased platelet aggregability in patients with vertigo, sudden deafness and facial palsy. Acta Otolaryngol Suppl 1995; 520: 399-400.